Product Sales
Full Year 2018 Product Sales
Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in eye care and generics products.
Read more about the 2018 sales of our top 20 Innovative Medicines products in the table below.
| Brands | Net Sales (USD m) | % change (cc) | Business Franchise |
|---|---|---|---|
| Gilenya | 3,341 | 4% | Neuroscience |
| Cosentyx | 2,837 | 36% | Immunology, Hepatology & Dermatology |
| Lucentis | 2,046 | 7% | Ophthalmology |
| Tasigna | 1,874 | 1% | Oncology |
| Sandostatin | 1,587 | -2% | Oncology |
| Gleevec/Glivec | 1,561 | -20% | Oncology |
| Afinitor/Votubia | 1,556 | 2% | Oncology |
| Galvus | 1,284 | 6% | Established Medicines |
| Promacta/Revolade | 1,174 | 35% | Oncology |
| Tafinlar/Mekinist | 1,155 | 31% | Oncology |
| Exjade/Jadenu | 1,099 | 3% | Oncology |
| Entresto | 1,028 | 102% | Cardio-Metabolic |
| Xolair | 1,039 | 12% | Respiratory |
| Diovan Group | 1,023 | 7% | Established Medicines |
| Exforge Group | 1,002 | 4% | Established Medicines |
| Jakavi | 977 | 24% | Oncology |
| Votrient | 828 | 2% | Oncology |
| Ilaris | 554 | 39% | Immunology, Hepatology & Dermatology |
| Travoprost Group | 517 | -12% | Ophthalmology |
| Zortress/Certican | 464 | 12% | Immunology, Hepatology & Dermatology |